IQVIA Holdings Inc. (NYSE:IQV) Receives $231.80 Average Target Price from Analysts

IQVIA Holdings Inc. (NYSE:IQV) has been assigned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $231.1250.

A number of analysts recently weighed in on IQV shares. TD Cowen raised their price target on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Barclays lowered their target price on IQVIA from $230.00 to $210.00 and set an “equal weight” rating for the company in a research note on Friday, February 6th. Royal Bank Of Canada initiated coverage on IQVIA in a research note on Tuesday. They set an “outperform” rating and a $221.00 price target on the stock. JPMorgan Chase & Co. lowered their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Finally, Evercore restated an “outperform” rating and set a $225.00 target price on shares of IQVIA in a research report on Thursday, February 5th.

Institutional Trading of IQVIA

Several institutional investors and hedge funds have recently made changes to their positions in the business. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA in the 4th quarter worth $25,000. Physician Wealth Advisors Inc. boosted its holdings in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth about $27,000. Gilpin Wealth Management LLC bought a new stake in shares of IQVIA in the 4th quarter valued at about $27,000. Finally, CrossGen Wealth LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $28,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 2.4%

IQV stock opened at $178.13 on Monday. The business has a fifty day moving average price of $209.22 and a 200 day moving average price of $207.69. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The stock has a market capitalization of $30.23 billion, a price-to-earnings ratio of 22.66, a P/E/G ratio of 1.68 and a beta of 1.39.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same quarter in the prior year, the business earned $3.12 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.